In 2024, Jointown Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Jointown Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 36,924.21a |
Total Scope 2 | |
Unspecified Calculation Method | 11,005.2a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.7751a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Jointown Pharmaceutical Group amounted to 47,929.41 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of Jointown Pharmaceutical Group were 36,924.21 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, Jointown Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 11,005.2 tCO₂e without specifying the calculation method.a
In 2024, Jointown Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Jointown Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 36,924.21 tCO₂e and total revenues of USD 20,801 millions. This translates into an emissions intensity of 1.78 tCO₂e per millions USD.a
In 2024, Jointown Pharmaceutical Group reported a Scope 1 emissions intensity of 1.78 tCO₂e per millions USD. Compared to the peer group median of 0.73, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Jointown Pharmaceutical Group ranked 17 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Jointown Pharmaceutical Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a